Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Trial Profile

AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rencofilstat (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms AMBITION
  • Sponsors Hepion Pharmaceuticals

Most Recent Events

  • 16 Mar 2023 According to a Hepion Pharmaceuticals media release, the company participate in American Chemical Society and the Joseph Priestley Society (ACS-JPS) webinar to present a data from this study and AI drug development.
  • 16 Mar 2023 According to a Hepion Pharmaceuticals media release, data from this study was used to design ongoing phase 2b ASCEND-NASH trial.
  • 08 Nov 2022 Results of multi-omics analysis presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top